Puma Biotechnology | PBYI - Net Income


Puma Biotechnology reported $20.32M in Net Income for its fiscal quarter ending in September of 2024.





Net Income Change Date
Agios Pharmaceuticals USD -108.04M 4.61M Dec/2025
Alnylam Pharmaceuticals USD 186.42M 64.66M Dec/2025
Amgen USD 1.33B 1.88B Dec/2025
Biogen USD 466.5M 168.3M Sep/2025
BioMarin Pharmaceutical USD -46.57M 15.83M Dec/2025
Daiichi Sankyo JPY 86.63B 41.32B Dec/2025
Esperion Therapeutics USD 61.83M 93.16M Dec/2025
Exelixis USD 193.58M 8.73M Sep/2025
Gilead Sciences USD 2.18B 869M Dec/2025
Glaxosmithkline GBP 846.06M 1.87B Dec/2025
Incyte USD 299.28M 124.89M Dec/2025
MacroGenics USD -14.16M 30.98M Dec/2025
Moderna USD -200M 625M Sep/2025
Novartis USD 2.41B 1.52B Dec/2025
Pfizer USD -1.65B 5.19B Dec/2025
PTC Therapeutics USD -134.96M 150.86M Dec/2025
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Roche Holding CHF 5.47B 1.76B Dec/2025
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Sarepta Therapeutics USD -412.23M 232.28M Dec/2025
Takeda JPY 103.64B 115.44B Dec/2025
TG Therapeutics USD 23.04M 367.86M Dec/2025
Ultragenyx Pharmaceutical USD -129M 51.41M Dec/2025
Vanda Pharmaceuticals USD -18.9M 13.58M Dec/2024
Vertex Pharmaceuticals USD 1.19B 108.2M Dec/2025